These combined findings indicate that pharmacological inhibition of oncogenic ERK signaling in cancer induces the transactivation of AKT through PHLDA1/2 downregulation, thereby leading to resistance of cancer cells to ERK pathway inhibitors. This evidence concerns the gene AKT1 and cancer.